Osteogenesis imperfecta (OI) is a rare connective tissue disease that primarily appears in bone, preceded with collagen abnormalities, characterized genetically. During the anesthetic management of these patients, intubation difficulties, cervical spine fractures, and malignant hyperthermia triggered by used anesthetic agents may develop. Taking the necessary measures in these patients, avoiding formation of new fractures during airway management, and to prevent hyperthermia intravenous agents can be thought instead of inhalation agents. Dexmedetomidine, is a sedative agent that provides smooth extubation conditions, and can be applied to TIVA as a third agent due to this property. In this case, we present our experience for adding dexmedetomidine to total intravenous anesthesia as an adjuvant to the patient with OI undergoing orthopedic surgery.
|Translated title of the contribution||Dexmedetomidine use in total intravenous anesthesia in a case with osteogenesis imperfecta|
|Number of pages||3|
|State||Published - 2012|
All Science Journal Classification (ASJC) codes
- Anesthesiology and Pain Medicine